期刊文献+

口服Ⅰ型Ⅲ型脊髓灰质炎减毒活疫苗的稳定性 被引量:2

Stability of typesⅠand Ⅲ oral live attenuated poliomyelitis vaccine
原文传递
导出
摘要 目的考察口服Ⅰ型Ⅲ型脊髓灰质炎减毒活疫苗在不同温度和pH环境下的稳定性。方法将6批疫苗分别于2~8℃放置6个月、22~25℃放置7 d、37℃放置7 d、-20℃放置27、30、33个月,或反复冻融5次;将疫苗pH调至3.0~10.0。采用细胞培养半数感染量(cell culture infective dose 50%,CCID50)法检测病毒总滴度及分型滴度。结果口服二价脊髓灰质炎减毒活疫苗在2~8℃保存6个月,22~25℃保存5 d,37℃保存2 d,反复冻融5次,-20℃保存27个月,pH 3.0~10.0环境下,疫苗效力均符合质量标准。结论疫苗的保存温度及时间对其稳定性均有影响。 Objective To evaluate the stability of oral live attenuated poliomyelitis vaccine at various temperatures and pH values.Methods Six batches of vaccines were stored at 2~8℃ for 6 months,22~25℃ for 7 d,37℃ for 7 d,and at-20℃ for 27,30 and 33 months,respectively,or were repeatedly frozen and thawed for 5 times.The pH values of vaccines were adjusted to 3.0~10.0.The total virus titer and the virus titers of various types of the vaccines were determined by median cell culture infective dose(CCID50)methods.Results The potency of the vaccine met the quality standard after storage at 2~8℃ for 6 months,at 22~25℃ for 5 d,at 37℃ for 2 d,after repeat freezing and thawing for 5 times,after storage at-20℃ for 27 months,or after adjustment of pH value to 3.0~10.0.Conclusion Both the temperature and time for storage showed influence on the stability of vaccine.
作者 刘悦越 赵岩 杜加亮 张韵祺 范行良 刘艳 于晴川 高加梅 国泰 LIU Yue-yue;ZHAO Yan;DU Jia-liang;ZHANG Yun-qi;FAN Xing-liang;LIU Yan;YU Qing-chuan;GAO Jia-mei;GUO Tai(The Department of Enteric Virus Vaccine,National Institutes for Food and Drug Control,Beijing 102629,China)
出处 《中国生物制品学杂志》 CAS CSCD 2019年第11期1195-1200,1205,共7页 Chinese Journal of Biologicals
基金 《中国药典》药品标准提高课题(358) 国家科技重大专项“重大新药创制”(2018ZX09739002-002)
关键词 脊髓灰质炎 二价疫苗 稳定性 Poliomyelitis Bivalent vaccine Stability
  • 相关文献

参考文献1

二级参考文献6

  • 1WHO MediaCentre.Poliomtelitis[R].Geneva:WHO 2014,No.114. 被引量:1
  • 2World Health Organization.Guidelines on stability evaluation of vaccines[R].Geneva:WHO,2006,23-27. 被引量:1
  • 3World Health Organization.Guidelines for clinical evaluation of vaccines:regulatory expectations[R].Geneva:WHO Technical Report Series,2004,No.924,Annex 1. 被引量:1
  • 4World Health Organization.Guidelines on nonclinical evaluation of vaccines[R].Geneva:WHO TechnicalReport Series,2005,No.927. 被引量:1
  • 5World Health Organization.Recommendations to assure the quality,safety and efficacy of live attenuated poliomyelitis vaccine(oral)[R].Geneva:WHO,2012,Annex1. 被引量:1
  • 6北京天坛生物制品股份有限公司.YBS00022013口服脊髓灰质炎减毒活疫苗(人二倍体细胞)注册标准[S].北京:北京天坛生物制品股份有限公司,2013. 被引量:1

共引文献10

同被引文献10

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部